Protection of the Human Gut Microbiome From AntibioticsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study evaluated DAV132, a product designed to deliver activated charcoal to the late ileum, as a means of protecting the gut microbiome during antibiotic treatment. Researchers tested whether coadministering DAV132 with the fluoroquinolone antibiotic moxifloxacin could adsorb residual antibiotic in the gut and limit its disruption of the intestinal microbiota. The trial also assessed plasma drug levels and safety, and separately tested DAV132's ability to adsorb other antibiotics outside the body.
Who was studied?
The study enrolled 28 human volunteers who received a 5-day clinical regimen of moxifloxacin, split into two parallel groups, one receiving DAV132 alongside the antibiotic and one not. Two additional control groups of 8 volunteers each received either DAV132 alone or a nonactive substitute. All participants appear to be healthy volunteers rather than patients with an existing condition.
What were the most important findings?
Coadministration of DAV132 reduced free moxifloxacin concentrations in feces by 99%, while plasma drug levels were unaffected, indicating the effect was localized to the gut and did not interfere with systemic antibiotic action. Shotgun quantitative metagenomics showed that the richness and composition of the intestinal microbiota were largely preserved in subjects who received DAV132 with moxifloxacin. No adverse effects were observed, and DAV132 also efficiently adsorbed a wide range of clinically relevant antibiotics in ex vivo testing.
What are the greatest implications of this study?
These findings suggest DAV132 could be a practical tool for protecting the gut microbiome during antibiotic therapy without reducing the antibiotic's systemic availability or efficacy. Because DAV132 adsorbed multiple other antibiotics ex vivo, this approach may generalize beyond moxifloxacin to broader clinical use. Preserving microbiota richness and composition during antibiotic courses could help mitigate the short-term and longer-term consequences of antibiotic-associated microbiome disruption.